Utility of individualized carboplatin dosing alone and in combination regimens
- PMID: 1411624
Utility of individualized carboplatin dosing alone and in combination regimens
Abstract
Carboplatin represents an ideal candidate for dose optimization in individual patients. The excellent correlations between renal function and carboplatin total body clearance and between carboplatin area under the plasma concentration by time curve (AUC) and thrombocytopenia allow calculation of carboplatin dosages that simultaneously minimize the likelihood of toxicity and maximize the amount of drug that can be delivered. Current studies are defining the essential relationship between carboplatin AUC and the likelihood of achieving a therapeutic response in various tumor types. These quantitative relationships between carboplatin AUC and thrombocytopenia and AUC and response should be the foundation for the intelligent use of carboplatin as an individual agent and for the intelligent assessment of the beneficial or adverse effects of other agents when combined with carboplatin.
Similar articles
-
[Dose individualization for carboplatin in cancer chemotherapy].Bull Cancer. 1997 Jun;84(6):675-7. Bull Cancer. 1997. PMID: 9295872 French.
-
Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.J Clin Oncol. 1993 Jun;11(6):1156-64. doi: 10.1200/JCO.1993.11.6.1156. J Clin Oncol. 1993. PMID: 8501502 Clinical Trial.
-
Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.BMC Cancer. 2017 Jun 8;17(1):407. doi: 10.1186/s12885-017-3394-2. BMC Cancer. 2017. PMID: 28595616 Free PMC article. Clinical Trial.
-
Phase I. Trial of irinotecan plus carboplatin in two dose schedules.Oncology (Williston Park). 2003 May;17(5 Suppl 5):36-40. Oncology (Williston Park). 2003. PMID: 12800605 Review.
-
Clinical pharmacokinetics and dose optimisation of carboplatin.Clin Pharmacokinet. 1997 Sep;33(3):161-83. doi: 10.2165/00003088-199733030-00002. Clin Pharmacokinet. 1997. PMID: 9314610 Review.
Cited by
-
Head and neck cancer: guidelines for chemotherapy.Drugs. 1996 Jan;51(1):73-88. doi: 10.2165/00003495-199651010-00006. Drugs. 1996. PMID: 8741233 Review.
-
Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer.Br J Cancer. 2003 Sep 1;89(5):787-94. doi: 10.1038/sj.bjc.6601215. Br J Cancer. 2003. PMID: 12942106 Free PMC article.